BC Week In Review | Jan 4, 2010
Clinical News

Celtura: Phase I data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: Celtura   Business: Infectious   Molecular target: Not applicable   Description: MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine   Indication: Vaccinate against swine influenza A (H1N1)...
BC Week In Review | Jan 4, 2010
Clinical News

Celtura regulatory update

Novartis said its influenza A (H1N1) 2009 monovalent vaccines Celtura, Focetria and Fluvirin received prequalification from the World Health Organization (WHO) for use in national immunization programs, which makes vaccines available for purchase through United...
BC Week In Review | Nov 23, 2009
Clinical News

Focetria: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 3.75 µg dose of Focetria met immune response criteria in children ages 3 to 8 at day 22. The trial enrolled 1,360...
BC Week In Review | Nov 23, 2009
Clinical News

Focetria: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 7.5 µg dose of unadjuvanted swine influenza A (H1N1) vaccine met immune response criteria in adults and elderly subjects >=18 years old....
BC Week In Review | Nov 23, 2009
Clinical News

Swine influenza A: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 7.5 µg dose of unadjuvanted swine influenza A (H1N1) vaccine met immune response criteria in adults and elderly subjects >=18 aged years....
BC Week In Review | Nov 9, 2009
Clinical News

Celtura regulatory update

Novartis said it received German marketing approval for Celtura, an MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine. The company said it is also pursuing approval of the vaccine in other countries, including Japan and...
BC Extra | Nov 6, 2009
Company News

Germany approves Novartis' Celtura

Novartis AG (NYSE:NVS; SIX:NOVN) said the German regulatory authorities approved Celtura , an MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine. The pharma said it continues to pursue approval of the vaccine in other countries, including...
BC Week In Review | Sep 7, 2009
Clinical News

Celtura: Pilot trial data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: Celtura   Business: Infectious   Molecular target: Not applicable   Description: MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine   Indication: Vaccinate against swine influenza A (H1N1)...
BC Extra | Sep 4, 2009
Clinical News

Novartis reports H1N1 vaccine data

Novartis AG (NYSE:NVS; SIX:NOVN) said data from a pilot trial in 100 healthy volunteers showed that Celtura induced hemagglutination-inhibition titers of at least 1:40 in 80% of subjects after one dose and more than 90%...
Items per page:
1 - 9 of 9